Popular on Rezul
- West Bend Area Real Estate Agent Promotes Homes To MORE Buyers For MORE Money
- Karen Hatcher Awarded REALTOR® of the Year by Atlanta REALTORS® Association
- Built In Honors Purchasing Platform in Its Esteemed 2023 Best Places To Work Awards
- Coldwell Banker Premier Realty Donates Thousands of Socks to Homeless Youth
- Ty'Shawn Brooks – United Real Estate
- Sammy Vélez's New Single "Cajón, Guitarra Y Son" To Be Released Worldwide On January 27th
- Mizner Country Club Offers Another Technogym Fitness And Wellness First – Virtual Spin
- Graphic Connections Group's Jeff Charlton Named to Titan 100
- Astro Dunia Launches Annual Letter 2023: A Financial Astrology Solution for Investors
- St. Louis-based hotel operator, Genuine Hospitality, LLC selected to operate the 120-room SpringHill Suites by Marriott Waukegan / Gurnee
Similar on Rezul
- Texas Automotive Lift & Equipment Distributor chooses Employees Ownership
- Paramount Completes Acquisition of First National ATM
- Fintech Startup BeFiSc Launches AI/ML Powered KYC Solutions Beyond Financial Scores
- Yida Gao and Shima Capital Celebrate Portfolio Company's Successful NFT Sellout
- The Case For Bonds As Part Of A Portfolio
- Cardinal Analytics Launches on the Bloomberg App Portal
- Orbex to Exhibit as Diamond Sponsor at the Fintech & Crypto Summit Bahrain, 2023
- Yida Gao, Shima Capital Recognized for Prolific Deal Activity
- STS Capital Partners Announces Sean Friday as New Chief Executive Officer
- ATM Processing Provider DNS Certifies Just.Cash Bitcoin Program
Ysios Capital strengthens its team with internal promotions and a new Venture Partner
Rezul News/10615021
Jordi Xiol has been promoted to Partner after joining Ysios Capital in 2019 and Salvatore Scaffidi, who joined the Ysios Fellowship program in 2020, has been promoted to Associate.
Ysios is also incorporating Sanifit co-founder and CEO Joan Perelló as Venture Partner.
These appointments add operational capacities supporting Ysios' mission to build leading life sciences companies.
Ysios is also incorporating Sanifit co-founder and CEO Joan Perelló as Venture Partner.
These appointments add operational capacities supporting Ysios' mission to build leading life sciences companies.
BARCELONA, Spain - Rezul -- Ysios Capital, a European life sciences venture capital firm, today announced the promotions of Jordi Xiol to Partner and Salvatore Scaffidi to Associate, as well as the appointment of Joan Perelló as Venture Partner.
Jordi Xiol joined Ysios Capital in 2019 as an Associate and his contribution to the identification and evaluation of investment opportunities has been outstanding. Prior to joining Ysios, Jordi worked at Vida Ventures in Boston, where he focused on opportunities in oncology, gene therapy, and ophthalmology. In his new role he will be responsible for making and managing investments. He is currently a member of the board of directors of Northsea Therapeutics and Splice Bio, and an observer on the board of directors of Adcendo and Cytoki.
More on Rezul News
Salvatore Scaffidi joined Ysios Capital in 2021 as an Analyst after successfully completing Ysios' Fellowship program. Prior to joining Ysios, Salvatore received a PhD from the University of Barcelona (UB), where he studied protein-ligand complexes using biophysical techniques. As an Associate, he will source and evaluate investment opportunities. Salvatore is currently a board observer at Splice Bio.
"The human capital is our key and only asset. These promotions reflect our commitment to foster and value top talent." commented Joël Jean-Mairet, Managing Partner at Ysios Capital.
Joan Perelló, a highly accomplished serial life sciences entrepreneur, has been appointed as a new Venture Partner at Ysios Capital. With 15+ years of management experience in various organizations, including as CEO, Non-Executive Director, President and Chairman, Joan Perelló is a respected figure in the life sciences industry. He is co-founder and CEO of Sanifit, a biotech company that raised over €140M in equity and debt financing before it was acquired by Vifor for €375M + sales milestones, the biggest exit of the Spanish Biotech sector. Joan is Chairman of the Board at CIRCE Crystal Engineering, President of the Balearic Cluster of Biotechnology and Biomedicine and Vice-Dean at the Official College of Chemists in the Balearic Islands, Spain.
More on Rezul News
Joan Perelló holds an MSc in Chemistry with first-class honors and earned his PhD from the University of the Balearic Islands, Spain, where he teaches Analytical and Clinical Chemistry as an Associate Professor.
"I have known the Ysios team for over a decade and have long admired their work in building Europe's, and in particular Spain's, leading life sciences companies. With their strong brand, international network, and excellent scientific backgrounds, they transform capital into medical breakthroughs." commented Joan Perelló, Venture Partner at Ysios Capital.
Julia Salaverria, Managing Partner at Ysios also added: "Joan is a highly accomplished serial entrepreneur and has created one of the key success stories in Spain. We are honored to be working with him as we continue to build leading life sciences companies."
Joan Perelló will join Ysios Capital Venture Partners' base of internationally renowned experts currently formed by Toni Ribas, world expert in immuno-oncology, former President of the American Association for Cancer Research (AACR) and Professor at the University of California Los Angeles (UCLA); Pamela Klein, former VP Development at Genentech/Roche; Carlos Payá, expert in Immunology and infectious diseases, previously in various leadership roles at Eli Lilly in and CEO of Immune Design until its acquisition by Merck & Co., David Lacey, former Senior VP and Global Head of Discovery Research at Amgen, and Lance Berman who has more than 20 years of clinical development experience in big pharma and the biotech start-ups.
Jordi Xiol joined Ysios Capital in 2019 as an Associate and his contribution to the identification and evaluation of investment opportunities has been outstanding. Prior to joining Ysios, Jordi worked at Vida Ventures in Boston, where he focused on opportunities in oncology, gene therapy, and ophthalmology. In his new role he will be responsible for making and managing investments. He is currently a member of the board of directors of Northsea Therapeutics and Splice Bio, and an observer on the board of directors of Adcendo and Cytoki.
More on Rezul News
- Planitar Inc., the Makers of iGUIDE, Introduces Instant 3D Virtual Tour Product and AI Automated Floor Plan Drafting Technology
- Louisville Riverport Authority Applies To Include South Central Kentucky In Foreign Trade Zone #29 Service Area
- Meg Matthews Joins DeRonja Real Estate
- IntellaTriage Hires New Director of Clinical Operations
- Metro Commercial brokers deal for BJ's Wholesale Club in West Palm Beach, FL
Salvatore Scaffidi joined Ysios Capital in 2021 as an Analyst after successfully completing Ysios' Fellowship program. Prior to joining Ysios, Salvatore received a PhD from the University of Barcelona (UB), where he studied protein-ligand complexes using biophysical techniques. As an Associate, he will source and evaluate investment opportunities. Salvatore is currently a board observer at Splice Bio.
"The human capital is our key and only asset. These promotions reflect our commitment to foster and value top talent." commented Joël Jean-Mairet, Managing Partner at Ysios Capital.
Joan Perelló, a highly accomplished serial life sciences entrepreneur, has been appointed as a new Venture Partner at Ysios Capital. With 15+ years of management experience in various organizations, including as CEO, Non-Executive Director, President and Chairman, Joan Perelló is a respected figure in the life sciences industry. He is co-founder and CEO of Sanifit, a biotech company that raised over €140M in equity and debt financing before it was acquired by Vifor for €375M + sales milestones, the biggest exit of the Spanish Biotech sector. Joan is Chairman of the Board at CIRCE Crystal Engineering, President of the Balearic Cluster of Biotechnology and Biomedicine and Vice-Dean at the Official College of Chemists in the Balearic Islands, Spain.
More on Rezul News
- L-Strategies political and business consulting firm launched by partners Angie Wong and Jared Craig with Donna and Stan Fitzgerald
- Zilker Partners Expands Recruiting and Digital Marketing Services to Keep Pace with Changing Business Climate
- Dental Tourism is on the Rise and This Dental Hygienist is Providing the Consultations
- California Closets of North Carolina and Virginia Helping Customers Get Organized
- New Book Launches to Bestseller Status--Answers the Question "Why Is It So Hard to Find Quality Workers?"
Joan Perelló holds an MSc in Chemistry with first-class honors and earned his PhD from the University of the Balearic Islands, Spain, where he teaches Analytical and Clinical Chemistry as an Associate Professor.
"I have known the Ysios team for over a decade and have long admired their work in building Europe's, and in particular Spain's, leading life sciences companies. With their strong brand, international network, and excellent scientific backgrounds, they transform capital into medical breakthroughs." commented Joan Perelló, Venture Partner at Ysios Capital.
Julia Salaverria, Managing Partner at Ysios also added: "Joan is a highly accomplished serial entrepreneur and has created one of the key success stories in Spain. We are honored to be working with him as we continue to build leading life sciences companies."
Joan Perelló will join Ysios Capital Venture Partners' base of internationally renowned experts currently formed by Toni Ribas, world expert in immuno-oncology, former President of the American Association for Cancer Research (AACR) and Professor at the University of California Los Angeles (UCLA); Pamela Klein, former VP Development at Genentech/Roche; Carlos Payá, expert in Immunology and infectious diseases, previously in various leadership roles at Eli Lilly in and CEO of Immune Design until its acquisition by Merck & Co., David Lacey, former Senior VP and Global Head of Discovery Research at Amgen, and Lance Berman who has more than 20 years of clinical development experience in big pharma and the biotech start-ups.
Source: Ysios Capital Partners
Filed Under: Financial
0 Comments
Latest on Rezul News
- VSA Prospecting Launches New Website, Enhancing the User Experience
- Yida Gao and Shima Capital Celebrate Portfolio Company's Successful NFT Sellout
- Quattro Development sells Lynwood, WA redevelopment site
- Berkshire Hathaway HomeServices Florida Network Realty Reveals New Global Brand Identity
- "Murdaugh Murders Podcast" Launches Spinoff "Cup of Justice" and Skyrockets to Apple's #1 Podcast
- CPAC 2023 Congressional Candidate Forum Meet and Greet March 2nd at the historic University Club in DC
- IoT Observatory to host Plenary Session at 2023 InsurTech Hartford Symposium
- Introducing Renters Insurance Wizard for Landlords and Tenants
- Leading Residential Real Estate Company Announces Exceptional Agent Performance
- Eliza Neals "Candy Store" new spring single out February 14th Valentines Day 2023!
- Engel & Völkers Undergoes Merger in Melbourne
- Realtor Kimberly Mills Named Certified Charitable Real Estate Specialist (CCRES)
- The Case For Bonds As Part Of A Portfolio
- Berkshire Hathaway HomeServices FNR Achieves $1.6 Billion Sales Volume in 2022
- Cardinal Analytics Launches on the Bloomberg App Portal
- 24th Annual Super Bowl Soulful Celebration Returns On Feb. 8 With Patti LaBelle, Israel Houghton & The Players Choir, Honoring NFL QB Jalen Hurts
- Orbex to Exhibit as Diamond Sponsor at the Fintech & Crypto Summit Bahrain, 2023
- Photography Book Makes Black History Month Fun
- Historic Groundbreaking Documentary About Women Marathoners Released for Black History Month
- Agent Bureau Launches Revolutionary Real Estate Agent Search Platform